Free Trial
NASDAQ:URGN

Urogen Pharma (URGN) Stock Price, News & Analysis

Urogen Pharma logo
$19.44 -0.34 (-1.72%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$19.25 -0.19 (-1.00%)
As of 08/22/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Urogen Pharma Stock (NASDAQ:URGN)

Key Stats

Today's Range
$19.41
$19.99
50-Day Range
$12.96
$20.72
52-Week Range
$3.42
$21.01
Volume
1.04 million shs
Average Volume
1.06 million shs
Market Capitalization
$899.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00
Consensus Rating
Buy

Company Overview

Urogen Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

URGN MarketRank™: 

Urogen Pharma scored higher than 91% of companies evaluated by MarketBeat, and ranked 104th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Urogen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Urogen Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Urogen Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Urogen Pharma are expected to decrease in the coming year, from ($3.12) to ($3.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Urogen Pharma is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Urogen Pharma is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Urogen Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    16.26% of the float of Urogen Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Urogen Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Urogen Pharma has recently decreased by 1.65%, indicating that investor sentiment is improving.
  • Dividend Yield

    Urogen Pharma does not currently pay a dividend.

  • Dividend Growth

    Urogen Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.26% of the float of Urogen Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Urogen Pharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Urogen Pharma has recently decreased by 1.65%, indicating that investor sentiment is improving.
  • News Sentiment

    Urogen Pharma has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Urogen Pharma this week, compared to 12 articles on an average week.
  • Search Interest

    Only 6 people have searched for URGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Urogen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Urogen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $457,467.00 in company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of Urogen Pharma is held by insiders.

  • Percentage Held by Institutions

    91.29% of the stock of Urogen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Urogen Pharma's insider trading history.
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Urogen Pharma and its competitors with MarketBeat's FREE daily newsletter.

URGN Stock News Headlines

UroGen Pharma to Present at Upcoming Investor Conferences
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
UroGen Pharma: Targeting Profits In 2027
HC Wainwright Has Weak Outlook for Urogen Pharma Q3 Earnings
See More Headlines

URGN Stock Analysis - Frequently Asked Questions

Urogen Pharma's stock was trading at $10.65 at the beginning of 2025. Since then, URGN shares have increased by 82.5% and is now trading at $19.44.

Urogen Pharma (NASDAQ:URGN) released its earnings results on Thursday, August, 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.23. The firm had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative trailing twelve-month return on equity of 97,487.15% and a negative net margin of 164.44%.
Read the conference call transcript
.

Urogen Pharma (URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Top institutional investors of Urogen Pharma include Soleus Capital Management L.P. (4.72%), Acorn Capital Advisors LLC (2.72%), Menora Mivtachim Holdings LTD. (2.49%) and SG Americas Securities LLC (2.49%). Insiders that own company stock include Mark Schoenberg and Jason Drew Smith.
View institutional ownership trends
.

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Urogen Pharma investors own include Voyager Therapeutics (VYGR), AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/07/2025
Today
8/24/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:URGN
CIK
1668243
Fax
N/A
Employees
200
Year Founded
2004

Price Target and Rating

High Price Target
$47.00
Low Price Target
$16.00
Potential Upside/Downside
+64.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$126.87 million
Net Margins
-164.44%
Pretax Margin
-160.04%
Return on Equity
-97,487.15%
Return on Assets
-59.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.14
Quick Ratio
3.99

Sales & Book Value

Annual Sales
$90.40 million
Price / Sales
9.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.02) per share
Price / Book
-9.62

Miscellaneous

Outstanding Shares
46,260,000
Free Float
44,090,000
Market Cap
$899.29 million
Optionable
Optionable
Beta
1.12

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:URGN) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners